Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17069212 | 1.00 | TP53 (0.59) | TP53LMNAHTTTSHRMEN1 | |
| SCHEMBL16770543 | 1.00 | TP53 (0.59) | TP53LMNAHTTTSHRMEN1 | |
| SCHEMBL20365885 | 0.84 | TP53 (0.55) | TP53LMNAHTTMEN1KMT2A | |
| SCHEMBL19539103 | 0.83 | HTT (0.44) | TP53LMNAHTTTSHRMEN1 | |
| SCHEMBL681524 | 0.83 | TP53 (0.59) | TP53LMNAHTTTSHRMEN1 | |
| SCHEMBL18928638 | 0.82 | HTT (0.42) | TP53LMNAHTTTSHRMEN1 | |
| SCHEMBL13180776 | 0.82 | LMNA (0.39) | TP53LMNAHTTTSHRMEN1 | |
| SCHEMBL28926872 | 0.82 | TP53 (0.62) | TP53LMNAHTTTSHRMEN1 | |
| SCHEMBL8934270 | 0.82 | TP53 (0.57) | TP53LMNAHTTTSHRMEN1 | |
| SCHEMBL9593590 | 0.81 | LMNA (0.52) | TP53LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024112123-A1 | NOVEL COMPOUND AS SELECTIVE ESTROGEN RECEPTOR MODULATOR | 재단법인 대구경북첨단의료산업진흥재단 | 2024-05-30 | — | — | WO | disclosed |
| US-20230339964-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | NUVATION BIO INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-11584756-B2 | Heterocyclic compounds as BET inhibitors | NUVATION BIO INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210002293-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2021-01-07 | — | — | US | disclosed |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-01-07 | — | — | US | disclosed |
| US-20200361925-A1 | INHIBITORS OF BETA-HYDROXYLASE FOR TREATMENT OF CANCER | RHODE ISLAND HOSPITAL (US) | 2020-11-19 | — | — | US | disclosed |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10351555-B2 | Inhibitors of β-hydroxylase for treatment of cancer | MIDWESTERN UNIVERSITY (US) | 2019-07-16 | — | — | US | disclosed |
| EP-3498273-A1 | PHARMACEUTICAL COMPOSITION FOR MODULATING THE RESPONSE OF A GABA-A RECEPTOR | Universität Wien (AT) | 2019-06-19 | — | — | EP | disclosed |
| US-8309587-B2 | Piperidine and piperazine phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120178713-A1 | PHENYL SULPHONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-12 | — | — | US | disclosed |
| US-8163720-B2 | Pyrrolidinyl phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| US-6462248-B1 | THROUGH CONVERSION, ISOMERIZATION AND/OR ADSORPTIVE SEPARATION OF AROMATIC COMPOUNDS | TORAY INDUSTRIES, INC. (JP) | 2002-10-08 | — | — | US | disclosed |
| EP-0985649-A2 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES, INC. (JP) | 2000-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178713-A1 | PHENYL SULPHONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, TRPA1, TRPV5 | TP53 4688/4885LMNA 4119/4885HTT 406/4885 |
| US-11584756-B2 | Heterocyclic compounds as BET inhibitors | BET1, BRD4, BRD3 | TP53 199/4885LMNA 2465/4885HTT 585/4885 |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | TP53 4485/4885LMNA 4172/4885HTT 836/4885 |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, TRPA1 | TP53 4544/4885LMNA 3348/4885HTT 469/4885 |
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | TP53 4485/4885LMNA 4172/4885HTT 836/4885 |
| US-20230339964-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | BET1, BRD4, BRD3 | TP53 199/4885LMNA 2465/4885HTT 585/4885 |
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC1R, MC3R, MC2R | TP53 4155/4885LMNA 4495/4885HTT 973/4885 |
| US-20210002293-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | BET1, BRD4, BRD3 | TP53 199/4885LMNA 2465/4885HTT 585/4885 |
| US-10351555-B2 | Inhibitors of β-hydroxylase for treatment of cancer | ASPH, CYP46A1, AHR | TP53 828/4885LMNA 2362/4885HTT 1608/4885 |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | TP53 4485/4885LMNA 4172/4885HTT 836/4885 |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | TP53 4485/4885LMNA 4172/4885HTT 836/4885 |
| US-20200361925-A1 | INHIBITORS OF BETA-HYDROXYLASE FOR TREATMENT OF CANCER | ASPH, CYP46A1, ALDH7A1 | TP53 873/4885LMNA 2397/4885HTT 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.